YahooOctober 6, 2026 at 10:53 AM NY21 Days Ago
Jaguar Health Targets Mid-2027 MVID NDA Filing as Crofelemer Intestinal Failure Program Advances
Jaguar Health subsidiary Napo Pharmaceuticals is continuing its global crofelemer development program for rare intestinal failure diseases while preparing for a planned mid-2027 New Drug Application filing for microvillus inclusion disease. Key Investor TakeawaysJaguar Health (NASDAQ:JAGX) continues to target a mid-2027 MVID NDA filing for crofelemer powder for oral solution.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
